Bristol-Myers Squibb India – Gurgaon

Bristol-Myers Squibb India Private Limited (BMS India) operates its India headquarters from Gurgaon, Haryana. BMS is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines for patients with serious diseases. In India, BMS focuses on oncology, immunology, and cardiovascular disease.

Products & Therapeutic Focus

BMS India’s flagship products include Opdivo (nivolumab) and Yervoy (ipilimumab) for oncology immunotherapy, Eliquis (apixaban) for anticoagulation, Revlimid (lenalidomide) and Pomalyst for haematological malignancies, and Orencia (abatacept) for rheumatoid arthritis. BMS has been instrumental in bringing checkpoint inhibitor immunotherapy to India.

Innovation & Patient Access

BMS India is committed to expanding access to innovative oncology therapies and has active patient assistance programmes. The Gurgaon office drives regulatory, medical affairs, market access, and commercial strategies for the Indian market. BMS also collaborates with Indian research institutions and cancer centres.

Contact Information

Company: Bristol-Myers Squibb India Pvt. Ltd.
Location: Gurgaon (Gurugram), Haryana
Business Type: Global Biopharmaceutical Subsidiary – Oncology & Immunology